Reviewer's report

**Title:** Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux.

**Authors:**
- Bart J. Veldt (b.veldt@erasmusmc.nl)
- Johannes T. Brouwer (brouwerj@rdgg.nl)
- Michael Adler (madler@ulb.ac.be)
- Frederik Nevens (frederik.nevens@uz.kuleuven.ac.be)
- Peter Michielsen (peter.michielsen@ua.uia.ac.be)
- Dr Jean Delwaide (jacques.belaiche@chu.ulg.ac.be)
- Bettina E. Hansen (b.hansen@erasmusmc.nl)
- Prof Solko W. Schalm (s.schalm@erasmusmc.nl)

**Version:** 1  **Date:** 24 Jun 2003

**Reviewer:** Kim Krogsgaard

**Level of interest:** A paper whose findings are important to those with closely related research interests

**Advice on publication:** Accept without revision

This is a very well planned study that during the years 1992 to 1996 included a total of 121 patients with chronic hepatitis C. All patients had previously failed IFN monotherapy. In the study patients were randomised to 6 moths of i) IFN and ribavirin combination therapy or ii) ribavirin monotherapy or iii) ribavirin placebo.

As the authors phrase it, it is a 'belated' report and it is therefore not surprising that very little is added to our understanding of hepatitis C treatment. However, it is my firm belief that all well planned, clinical relevant studies should be reported and published.

Overall this is a clearly written manuscript which includes all necessary information. I have no specific comments our suggestions for the authors

**Competing interests:**

None declared.